Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment
- Posted on April 23, 2026
- By CNBC
- 0 Views
- 1 min read
In brief
Roche's leadership addresses the significant headwinds posed by Swiss franc appreciation on quarterly financial performance. The pharmaceutical giant is intensifying its strategic commitment to the United States market, recognizing it as a key growth driver despite macroeconomic challenges. Currency fluctuations continue impacting global drugmakers' profitability, prompting companies to recalibrate geographic investments and operational strategies to maintain competitive positioning.
Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment
Currency effects weighed on the Swiss drugmaker's first-quarter earnings
